The combination respiratory antigen test, which detects SARS-CoV-2, influenza A, and influenza B from a single nasal swab, has quietly become the default at-home and point-of-care expectation across the United States. The 2024-2025 respiratory season is the first in which most of the major retail and clinic-distributed rapid tests carry all three targets on a single cassette. The chemistry was not the difficult part. The clinical workflow change is what matters.
Three targets on one cassette is a categorically different test from three single-target tests run in sequence. The reason has to do with how primary care actually treats acute respiratory illness in the patient sitting in front of them.
Why differential matters at the point of care
For most adult patients with mild respiratory symptoms, the difference between COVID, flu A, flu B, and "viral, unspecified" does not change immediate management much. Supportive care is supportive care. The differential matters in three specific clinical contexts:
- Antiviral selection. Influenza A and B are treated with neuraminidase inhibitors (oseltamivir, baloxavir). COVID-19 is treated with nirmatrelvir-ritonavir or remdesivir. The decision to prescribe one versus the other turns on which virus is present.
- Risk stratification. Older adults, immunocompromised patients, and those with significant comorbidities benefit from knowing which virus they have, both for prognostic counseling and for monitoring intensity.
- Public health surveillance and household management. A flu A diagnosis in a household with vulnerable members produces different guidance than a COVID diagnosis. The exposure window, the duration of contagiousness, and the prophylaxis options differ.
A combination test that returns the answer in fifteen minutes during the visit is, in clinical-workflow terms, the difference between a treatment decision made now and one deferred to a phone call about a PCR result that arrives the next afternoon.
What the cassette is actually doing
A three-target lateral-flow cassette is, mechanically, three immunoassays running on the same membrane in parallel lanes. Each lane has its own conjugate pad with antibodies tuned to a different antigen (the SARS-CoV-2 nucleocapsid, an influenza A nucleoprotein, an influenza B nucleoprotein). The control line is shared. The read window shows three test lines, any combination of which can be positive.
The published sensitivity and specificity for combination cassettes from the major manufacturers, as cataloged by the FDA's IVD authorizations, generally land in ranges comparable to single-target rapid antigen tests. The slight cost is a small reduction in maximum sensitivity per target compared to a single-target test optimized for that one analyte. The benefit is the ability to make a clinical decision based on three results from one swab, in the same visit.
The combination cassette is not the most sensitive test for any single target. It is the most useful test for the patient sitting in the exam room.
What changed in the 2024-2025 season
Two operational shifts:
Combination cassettes are now the default in primary care purchasing. Single-target COVID-only and flu-only rapid tests are still available, but their share of purchasing has compressed. CLIA-waived combination tests dominate clinic ordering.
At-home combination tests have entered the retail channel. A patient with respiratory symptoms in early 2025 can buy a combination test at most pharmacies, run it at home, and arrive at a telehealth visit with a known result. This shifts the clinic conversation from "let's figure out what you have" to "given that you have flu A, here's what we do."
What to ask of a combination test
For programs and clinics evaluating combination respiratory antigen tests, three questions tend to surface the differences:
What is the limit of detection per target. The number that matters is sensitivity at viral concentrations actually present in early symptomatic disease, not theoretical analytic sensitivity at peak viral load.
What is the cross-reactivity profile. A flu A line that lights up faintly on certain coronavirus seasonal strains is a real-world calling problem. The package insert should document tested cross-reactants.
How does the test behave at days 1, 3, and 5 of symptoms. Antigen tests for respiratory viruses are most sensitive in the symptomatic peak. The specification should document expected performance across the symptomatic window.
The portfolio implication
Our team has worked on combination respiratory antigen tests since the early COVID-era. The transition from single-target to combination is not a technical revolution. It is a clinical-workflow optimization that took the pandemic-era infrastructure and pointed it at a routine question (which respiratory virus does this patient have) that primary care had been answering imprecisely for decades. The combination cassette is the right unit for the question. The chemistry caught up to the clinical need on a faster timeline than usual, mostly because the manufacturing infrastructure was already in place.
For 2026, the conversation is moving toward four-target cassettes that add RSV. The clinical case is the same: differential matters at the point of care, and a fifteen-minute answer is operationally different from a twenty-four-hour answer.